Cognoptix is pioneering a non-invasive diagnostic platform aimed at the early detection of Alzheimer’s disease through its innovative SAPPHIRE II system. This technology combines a laser eye scanning device with a fluorescent ointment that binds to beta-amyloid proteins, which are indicative of Alzheimer’s. The SAPPHIRE II system allows for the detection of amyloid deposits in the lens of the eye during a simple eye scan performed in a doctor's office. Clinical trials have demonstrated the system's high sensitivity and specificity in differentiating patients with probable Alzheimer’s from healthy individuals, showing promising results that correlate well with traditional PET scans, the current gold standard for detecting amyloid in the brain.

The underlying technique, known as Fluorescent Ligand Eye Scanning (FLES), involves administering a beta-amyloid-specific compound into the eye, which binds to amyloid aggregates in the lens. The SAPPHIRE device then excites these fluorescent ligands, allowing for quantitative measurements of the emitted light to confirm the presence of amyloid. This capability not only aids in the early diagnosis of Alzheimer’s but also enables ongoing monitoring of disease progression and the effectiveness of therapeutic interventions. Cognoptix's approach addresses a significant unmet need for a safe, simple, and cost-effective method for Alzheimer’s detection, positioning the company as a leader in the field of Alzheimer’s diagnostics.

United States

Cognoptix is pioneering a new way to see Alzheimer's disease (AD): a low-cost, practical and non-invasive eye scan that detects beta-amyloid deposits in the lens. Amyloid is the earliest biomarker of AD, and our system can detect it years or decades before amyloid appears in the brain.

Cognoptix_

Company Details